| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hua Yang, Haili W. Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia. Noro psikiyatri arsivi. vol 61. issue 4. 2024-12-16. PMID:39678059. |
meta-analysis of the efficacy of risperidone treatment in patients with first-episode schizophrenia. |
2024-12-16 |
2024-12-21 |
Not clear |
| Hua Yang, Haili W. Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia. Noro psikiyatri arsivi. vol 61. issue 4. 2024-12-16. PMID:39678059. |
this meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia. |
2024-12-16 |
2024-12-21 |
Not clear |
| Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzade. Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial. International clinical psychopharmacology. 2024-12-11. PMID:39661337. |
crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial. |
2024-12-11 |
2024-12-13 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. |
2024-12-05 |
2024-12-08 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
this study was devised to examine potential alterations in regional homogeneity (reho) that arise in schizophrenia patients with comorbid mets undergoing risperidone or clozapine treatment. |
2024-12-05 |
2024-12-08 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
in total, 43 schizophrenia patients undergoing risperidone or clozapine treatment were enrolled in this study, of whom 20 had comorbid mets (sz-mets) while 23 did not (sz-nmets). |
2024-12-05 |
2024-12-08 |
Not clear |
| Ozge Sezin Somuncu, Irem Karaman, Hilal Piril Saracoglu, Erdem Yilmaz, Demet Aki. Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids. Psychiatry and clinical psychopharmacology. vol 31. issue 1. 2024-12-02. PMID:39619356. |
modeling schizophrenia with glioblastoma cells: in vitro analysis of risperidone treatment on glial spheroids. |
2024-12-02 |
2024-12-06 |
Not clear |
| Ozge Sezin Somuncu, Irem Karaman, Hilal Piril Saracoglu, Erdem Yilmaz, Demet Aki. Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids. Psychiatry and clinical psychopharmacology. vol 31. issue 1. 2024-12-02. PMID:39619356. |
in the present study, the tumor spheroid technology is applied to two different glioblastoma lines which resemble schizophrenia manifestation along with the investigation of the potential anti-tumor effect of an atypical antipsychotic drug, risperidone. |
2024-12-02 |
2024-12-06 |
Not clear |
| Ozge Sezin Somuncu, Irem Karaman, Hilal Piril Saracoglu, Erdem Yilmaz, Demet Aki. Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids. Psychiatry and clinical psychopharmacology. vol 31. issue 1. 2024-12-02. PMID:39619356. |
our hypothesis built on case reports showing patients with schizophrenia being treated with risperidone that turned out to have glioblastoma in post-mortem evaluation. |
2024-12-02 |
2024-12-06 |
Not clear |
| Yongjie Zhong, Wenhui Wang, Miaomiao Zhang, Yitan Yao, Huanzhong Liu, Kai Zhan. Efficacy and safety of prophylactic use of benzhexol after risperidone treatment in MK-801-induced mouse model of schizophrenia. Psychopharmacology. 2024-11-17. PMID:39551830. |
efficacy and safety of prophylactic use of benzhexol after risperidone treatment in mk-801-induced mouse model of schizophrenia. |
2024-11-17 |
2024-11-22 |
mouse |
| Hiram Tendilla-Beltrán, Diana Laura Perez-Osornio, David Javier Apam Castillejos, Gonzalo Flore. Atypical antipsychotics improve dendritic spine pathology in temporal lobe cortex neurons in a developmental rodent model of schizophrenia. Behavioural brain research. 2024-11-16. PMID:39549876. |
the neonatal ventral hippocampus lesion (nvhl) in rats exhibits behavioral abnormalities akin to schizophrenia symptoms and corticolimbic dendritic spine pathology, mitigated by atypical antipsychotic drugs (aads) like risperidone (risp) and olanzapine (olz). |
2024-11-16 |
2024-11-20 |
rat |
| Zaihong Yang, Peifan Li, Hongyan Fan, Lan Pang, Guangyuan Xia, Changrong Duan, Lei Zhen. Risperidone accelerates bone loss in mice models of schizophrenia by inhibiting osteoblast autophagy. Heliyon. vol 10. issue 21. 2024-11-14. PMID:39524718. |
risperidone accelerates bone loss in mice models of schizophrenia by inhibiting osteoblast autophagy. |
2024-11-14 |
2024-11-17 |
mouse |
| Thomas Messer, Miquel Bernardo, Lourdes Anta, Javier Martínez-Gonzále. Risperidone ISM Therapeutic advances in psychopharmacology. vol 14. 2024-10-18. PMID:39421638. |
risperidone ism one of the most important challenges in the management of patients with schizophrenia is to ensure adherence to antipsychotic treatment. |
2024-10-18 |
2024-10-20 |
Not clear |
| Andreas Lindauer, Eric Snoeck, Christian Laveille, Ignacio Ayani, Lourdes Ochoa Díaz de Monasterioguren, Marcos Almendros, Javier Martínez-González, Lourdes Anta, Ibón Gutierr. Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. Journal of clinical pharmacology. 2024-10-17. PMID:39417209. |
exposure-efficacy analysis and dopamine d2 receptor occupancy in adults with schizophrenia after treatment with the monthly intramuscular injectable risperidone ism. |
2024-10-17 |
2024-10-19 |
Not clear |
| Andreas Lindauer, Eric Snoeck, Christian Laveille, Ignacio Ayani, Lourdes Ochoa Díaz de Monasterioguren, Marcos Almendros, Javier Martínez-González, Lourdes Anta, Ibón Gutierr. Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. Journal of clinical pharmacology. 2024-10-17. PMID:39417209. |
data from a phase iii trial were used to establish an exposure-response relationship for monthly intramuscular risperidone ism (75 and 100 mg) or placebo administered to adults with schizophrenia. |
2024-10-17 |
2024-10-19 |
Not clear |
| David P Walling, Ying Dong, Robert Litman, Wenyan Wang, Chunli Liu, Joe Tai, Pinglan Liu, Yanan Shi, Wanhui Liu, Fenghua Fu, Kaoxiang Su. Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder. Journal of clinical pharmacology. 2024-10-15. PMID:39404139. |
pharmacokinetics and safety of a novel extended-release microsphere formulation of risperidone in patients with schizophrenia or schizoaffective disorder. |
2024-10-15 |
2024-10-17 |
Not clear |
| David P Walling, Ying Dong, Robert Litman, Wenyan Wang, Chunli Liu, Joe Tai, Pinglan Liu, Yanan Shi, Wanhui Liu, Fenghua Fu, Kaoxiang Su. Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder. Journal of clinical pharmacology. 2024-10-15. PMID:39404139. |
risperidone extended-release injectable suspension (r-eris; marketed as rykindo) is a novel immediate-release version of risperidone formulated as extended-release microspheres for biweekly intramuscular injection to treat schizophrenia in adults. |
2024-10-15 |
2024-10-17 |
Not clear |
| Leslie Citrome, Mark Suett, Kelli R Franzenburg, Roy Eshet, Anna Elgart, Glen L Davis Rd, Eran Harary, Orna Tohami, Marko A Mychaskiw, John M Kan. TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia. Neuropsychiatric disease and treatment. vol 20. 2024-10-14. PMID:39399879. |
tv46000 is a long-acting subcutaneous antipsychotic (lasca) formulation of risperidone approved for the treatment of schizophrenia in adults. |
2024-10-14 |
2024-10-16 |
Not clear |
| Stefan Leucht, Josef Priller, John M Davi. Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application. The American journal of psychiatry. vol 181. issue 10. 2024-10-01. PMID:39350614. |
dose-response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with maximally efficacious average dosages for schizophrenia of around 5 mg/day risperidone equivalents. |
2024-10-01 |
2024-10-03 |
Not clear |
| Hasan Çağın Lenk, Elise Koch, Kevin S O'Connell, Robert Løvsletten Smith, Ibrahim A Akkouh, Srdjan Djurovic, Ole A Andreassen, Espen Molde. Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment. Human genomics. vol 18. issue 1. 2024-09-28. PMID:39334510. |
risperidone, another atypical antipsychotic with a more distinctive dopamine 2 antagonism, is commonly used in treatment of schizophrenia. |
2024-09-28 |
2024-10-01 |
Not clear |